Pathos AI, a biotech company focused on applying artificial intelligence to cancer treatment, has secured $365 million in Series D financing, increasing its post-money valuation to about $1.6 billion. The funding will support the expansion of its AI-enabled drug development platform and the advancement of its clinical-stage oncology pipeline. The company is also investing in its proprietary AI Foundation Model, designed specifically for oncology, to accelerate the development of new therapies.
Pathos AI is building the largest multimodal foundation model in oncology, using clinical, molecular, and imaging data to improve the process of selecting drug candidates, designing clinical trials, and identifying biomarkers. This approach aims to increase accuracy and efficiency in developing cancer treatments. CEO Iker Huerga stated, "With this financing, we’re building one of the most advanced AI engines, designed to accelerate development, deepen clinical insight, and ensure the right therapies reach the patients who need them most."
